Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of capecitabine + bevacizumab in elderly patients with advanced or metastatic colorectal adenocarcinoma
2005-002808-42Phase 2Active
- Sponsor
- Grupo Oncopaz
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and bevacizumab in colorectal adenocarcinoma, sponsored by Grupo Oncopaz. Primary endpoints: Overall response rate and Overall survival. Started Nov 2005; status: active.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2005-002808-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002808-42.